BIORCHESTRA, a biotherapeutics company focused on providing life-changing treatments to those suffering from rare and degenerative diseases within the Central Nervous System (CNS), has announced an exclusive collaboration with a leading biopharmaceutical company.
Through the combination of Biorchestra’s Drug Delivery System (BDDS™) – which utilises targeted cell delivery capabilities and proprietary RNA chemistries – and the biopharmaceutical company’s transformative medicines, the partnership will work to develop treatments for a single target, with the potential to expand the scope to include several others.
Dr. Branden Ryu, Scientific Founder, Chairman, and Chief Executive Officer, is thrilled to announce the start of a groundbreaking collaboration with a U.S. partner. This partnership will help accelerate the development of innovative new medicines to help improve the lives of patients worldwide.
Dr. Louis St. L. O’Dea, President and Chief Medical Officer of Biorchestra, believes that their suite of technologies, which enable IV-formulated, biological-barrier crossing therapeutics, are the perfect match for their partner’s new approach to next-generation medicines. This offers a promising potential to treat a range of diseases, setting a new standard in modern healthcare.
This exciting new partnership is a testament to the power of our transformational science and technology platform. Strategic partnerships are key to helping us bring our breakthrough innovations to the global pharmaceutical and biotech sector, and this collaboration is an essential step towards achieving that goal.
We are thrilled to be working with such a prestigious partner and look forward to the possibilities that this partnership will bring.
Destum Partners provided invaluable advice and guidance throughout the transaction, acting as trusted advisors to the Company.
About Biorchestra Drug Delivery System (BDDS™)
The BDDS™ platform, specifically formulated for IV administration, is revolutionizing the way we approach neurological diseases. By targeting an amino acid receptor in the blood-brain barrier, this innovative platform has already demonstrated functional outcomes in a non-human primate study of Alzheimer’s disease.
Additionally, it has been leveraged with Antisense Oligonucleotide and siRNA to validate significant knockdown of a target implicated in Amyotrophic Lateral Sclerosis and Parkinson’s disease. Our ongoing research is expanding the scope of BDDS™ to treat a variety of underserved diseases, including Glioblastoma multiforme, Lewy body dementia, Spinocerebellar ataxia type three, Frontotemporal dementia, and Progressive supranuclear palsy.
About BIORCHESTRA
BIORCHESTRA is revolutionizing the treatment of rare and degenerative diseases within the Central Nervous System through its proprietary BDDS™ and Brain-Targeting RNAi Nanomedicine (BTRiN™) platforms.
These cutting-edge technologies utilize targeted cell delivery and advanced RNA chemistries to unlock first-in-class therapeutics. BMD-001, the company’s lead program, is being developed to efficiently and effectively administer IV treatments targeting micro-RNAs linked to neuroinflammation, mitochondrial dysfunction, neurodegeneration, and amyloid protein deposition in Alzheimer’s diseasae and Amyotrophic Lateral Sclerosis.
BIORCHESTRA has major research and development facilities in Daejeon, South Korea, and a U.S. headquarters in Cambridge, Massachusetts, U.S.A. that are committed to providing innovative biomedical solutions.
About BMD-001
BMD-001, an IV formulation, is revolutionizing the treatment of neurological diseases. Proven to be effective in both rodent and primate models, BMD-001 is capable of suppressing specific microRNA, normalizing homeostatic processes, reducing amyloid and tau protein deposition, decreasing neuroinflammation, and improving cognitive function. This pioneering drug program is an innovative way to target neurological diseases and provide effective treatments.